Oritavancin for acute bacterial skin and skin structure infections.

about

Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.Infective endocarditis.

P2860

Q38646905-CEAC2167-0472-4137-A4C4-22B6A2F51A9F Q52943386-4F7F7CD6-DD6A-45F2-964C-CA7AEDBE4CA9

P2860

Oritavancin for acute bacterial skin and skin structure infections.

Item

http://www.wikidata.org/entity/Q36086423

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Oritavancin for acute bacterial skin and skin structure infections.

@ast

Oritavancin for acute bacterial skin and skin structure infections.

@en

type

Item

label

Oritavancin for acute bacterial skin and skin structure infections.

@ast

Oritavancin for acute bacterial skin and skin structure infections.

@en

altLabel

Oritavancin for acute bacterial skin and skin structure infections

@en

prefLabel

Oritavancin for acute bacterial skin and skin structure infections.

@ast

Oritavancin for acute bacterial skin and skin structure infections.

@en

P1476

Oritavancin for acute bacterial skin and skin structure infections.

@en

P2093

G Ralph Corey

http://www.w3.org/2001/XMLSchema#string

Julia A Messina

http://www.w3.org/2001/XMLSchema#string

P2860

Methicillin-resistant Staphylococcus aureus therapy: past, present, and future

The economic burden of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA).

Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis

Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis

A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study.

Incidence and cost of hospitalizations associated with Staphylococcus aureus skin and soft tissue infections in the United States from 2001 through 2009

Mixed-lipid storage disorder induced in macrophages and fibroblasts by oritavancin (LY333328), a new glycopeptide antibiotic with exceptional cellular accumulation

Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis.

Once-weekly dalbavancin versus daily conventional therapy for skin infection.

Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia.

P304

1091-1098

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.2015.1026256

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Vance G Fowler

P577

2015-03-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25803197

http://www.w3.org/2001/XMLSchema#string

P921

Staphylococcus aureus

oritavancin

P932

4580226

http://www.w3.org/2001/XMLSchema#string

Oritavancin for acute bacterial skin and skin structure infections.

about

P2860

P2860

Oritavancin for acute bacterial skin and skin structure infections.

description

name

type

label

altLabel

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932